MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST

Spatial Landscape of the Immune Microenvironment in Metastatic Prostate Cancer using GeoMx™ Digital Spatial Profiler

Speaker
  • Professor of Medicine at the University of Washington
    Biography
      Peter Nelson, MD is a Member of the Divisions of Human Biology and Clinical Research at the Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington.

    Abstract

    Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the heterogeneity and lack of understanding of the immune composition and tumor microenvironment (TME) within and between molecular subtypes.

    To characterize the immune TME of mPC, we obtained multiple metastases from patients with mPC belonging to multiple genomic subtypes and three phenotypes. Previous work defined the molecular subtype of each metastatic tumor by RNA-seq and whole exome sequencing, and patients were stratified to compare and contrast androgen receptor (AR) active tumors (AR+/NE-), neuroendocrine (NE) tumors (AR-/NE+), and double-negative tumors (AR-/NE-). An immuno-oncology RNA panel for the NanoString GeoMx™ Digital Spatial Profiler was used to determine the immune cell phenotypes within the tumor, in proximity to the tumor, and distant from the tumor margin.

    Here we present a map of the metastatic landscape in mPC patients, focusing on the organization of the immune cells within the tissue. We use these maps to determine the immune cell compositions, spatial organization of metastatic niches, and spatial expression signatures that associate with the molecular subtypes of mPC. We further characterized the expression patterns between metastatic sites within the same patient, as well as the variation between patients.

    Our study demonstrates a spatial genomics approach to defining the microenvironment landscape of molecular subtypes of mPC, potentially revealing patterns in the metastatic microenvironments that may predict the utility of immune-based therapies.

    GeoMxTM DSP technology is for Research Use Only and not for use in diagnostic procedures.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources
    Attendees
    • See more